RFS Failed as Endpoint in Adjuvant Immunotherapy Trials RFS Failed as Endpoint in Adjuvant Immunotherapy Trials

A new analysis found that relapse-free survival is a poor surrogate endpoint for overall survival in adjuvant immunotherapy trials in a variety of cancer types.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news